Top Markets
Coin of the day
Gyre Therapeutics, Inc. Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRE
Rank in Stocks #11143
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering,... Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Share Price
$6.61
Last synced: 2026-08-28
Market Cap
$736.94M
Change (1 day)
-1.05%
Change (1 year)
-14.60%
Country
US
Trade Gyre Therapeutics, Inc. (GYRE)

Category

Stock price history for Gyre Therapeutics, Inc. (GYRE)
Highest end of day price: $6.72 on 2026-08-01

Lowest end of day price: $12.50K on 2006-04-01
Stock price history of Gyre Therapeutics, Inc. from 2006 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -3.27%
2025 -32.25%
2024 -52.32%
2023 202.08%
2022 -50.65%
2021 -83.58%
2020 8.07%
2019 -33.68%
2018 -12.06%
2017 -1.82%
2016 -72.82%
2015 -85.70%
2014 -47.12%
2013 3.59%
2012 -31.84%
2011 -72.71%
2010 10.88%
2009 733.78%
2008 -69.18%
2007 13.36%
2006 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.53 -12.70%
AU
$138.18 473.58%
US
$759.27 7.20%
CH